Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.

about

Evaluation of the use of therapeutic peptides for cancer treatment Advancement and applications of peptide phage display technology in biomedical science RGD-mediated delivery of small-molecule drugs.Small Molecules for Active Targeting in Cancer.

P2860

Q29048586-BC94F0A6-3118-4DB5-AAF0-32804DB0937E Q35898339-8340D751-35BE-41EA-97C3-12E0B99A5742 Q38732486-82A2C5E3-6B09-4EF9-8116-CA721DF45507 Q38780383-02F8D279-9ECD-4D22-A88D-1857FE7DE20C

P2860

Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.

Item

http://www.wikidata.org/entity/Q39063433

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@en

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@nl

type

Item

label

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@en

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@nl

prefLabel

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@en

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@nl

P1476

Synthesis and biological evalu ...... egrin-targeted cancer therapy.

@en

P2093

Chao Wang

http://www.w3.org/2001/XMLSchema#string

Hongyan He

http://www.w3.org/2001/XMLSchema#string

Jianjun Hou

http://www.w3.org/2001/XMLSchema#string

Lihe Zhang

http://www.w3.org/2001/XMLSchema#string

Ping Xu

http://www.w3.org/2001/XMLSchema#string

Xiaoxiao Li

http://www.w3.org/2001/XMLSchema#string

Xinjie Liu

http://www.w3.org/2001/XMLSchema#string

Yun Wu

http://www.w3.org/2001/XMLSchema#string

Zhenjun Yang

http://www.w3.org/2001/XMLSchema#string

Zili Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Signaling by dual specificity kinases

Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity.

MAP kinase pathways.

Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclized through oxorhenium and oxotechnetium coordination.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

P304

13957-13978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/MOLECULES181113957

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258522394

http://www.w3.org/2001/XMLSchema#string

P698

24225774

http://www.w3.org/2001/XMLSchema#string

P932

6269693

http://www.w3.org/2001/XMLSchema#string

Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.

about

P2860

P2860

Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932